## ONTARIO HEALTH WEST COVID ASSESSMENT CENTRE: Outpatient COVID Therapy Referral Form MUST include accurate medication list with Form

	e fax completed form <u>AND</u> pa	tient's medication list t	o clinic		
PATIENT INFORMATION					
First Name	Last Name	Sex (at birth	) □ Male □ Fema	ale DOB	
Address	City	Health Card	No.	Version	
Postal Code Telephone		Preferred La	Preferred Language ☐ EN ☐ Other		
Allergies	Height (cm) Weight (Kg)				
NOTE: For patients with mild COVID-19 with confirmed COVID-19. These products are available for use under an interim authorization (Interim Order) by Health Canada to prevent progression of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Please check current patient eligibility here: <a href="https://covid-19.ontario.ca/covid-19-antiviral-treatment">https://covid-19.ontario.ca/covid-19-antiviral-treatment</a>					
Nirmatrelvir-Ritonavir (Paxlovid <sup>™</sup> ) is available through community physicians in association with pharmacies across Ontario <a href="https://covid-19.ontario.ca/covid-19-treatments">https://covid-19.ontario.ca/covid-19-treatments</a> ). The Paxlovid Prescription form can be accessed <a href="https://ehealthce.ca/COVID-Therapeutics.htm">https://ehealthce.ca/COVID-Therapeutics.htm</a> .					
REASON FOR REFERRAL					
THIS REFERRAL FORM SHOULD ONLY REASONS (PLEASE SELECT ALL THA'  ☐ Patient has no access to a provider w ☐ Patient is medically complex and has ☐ Patient requires IV Remdesivir (note of the complex in	T APPLY): vithin 5 days significant drug interactions (Pl this requires 3 consecutive days	lease specify:		FOR THE FOLLOWING	
INCLUSION CRITERIA: MUST MEET CRITERIA TO PROCEED WITH TREATMENT					
Date of symptom onset (Day 0) - must be 7 days or less: Positive COVID Test Completed (indicate test and date):					
□ PCR Date: □ Self-Administered RAT Date: □ Health Care Administered RAT Date: □ ID NOW:					
AGE (YEARS) 0, 1, OR 2		NUMBER OF VACCINE DOSES 2 DOSES 3 DOSES			
		or more risk factors	Not eligible	0 00000	
60 to 69	☐ Eligible		Not Eligible		
70 or greater	☐ Eligible		☐ Eligible		
Immunocompromised individuals of a age (18 years of age and older)	individuals no vaccination or	☐ Eligible: Therapeutics should always be recommended for immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying immune status, regardless of age or vaccine status.			
Dragnanav		0 DOSES		1,2, or 3 DOSES	
Pregnancy	☐ Eligible		Not Eligible		
Indigenous persons (First Nations, Inuit, or Métis), Black persons, and members of other racialized communities may be at high risk of disease progression due to disparate rates of comorbidity, increased vaccination barriers, and social determinants of health, and should be considered priority populations for access to COVID-19 therapeutics.					
Risk Factors: (Check all that applies)  ☐ Obesity (BMI greater than or equal to 30 kg/m²)  ☐ Diabetes  ☐ Heart disease, hypertension, congestive heart failure		Immunocompromise Factors: (Check all that applies)   Solid organ or bone marrow transplant (*)   CAR T-cell therapy   Anti-CD 20 agent   Alkylating agents anti-metabolites (*) (*) Depending on absolute			
<ul> <li>☐ Chronic respiratory disease, including cystic fibrosis</li> <li>☐ Cerebral palsy</li> <li>☐ Intellectual disability</li> </ul>		□ Alkylating agents, anti-metabolites (*) □ Advanced or untreated HIV □ Congenital immunodeficiency			
<ul> <li>☐ Sickle cell disease</li> <li>☐ Moderate or severe kidney disease (eGFR less than 60 ml/min)</li> <li>☐ Moderate or severe liver disease (e.g. Child-Pugh Class B or C)</li> </ul>		☐ Anti-TNF blockers or other biologic agents (*) ☐ Taking chronic oral corticosteroid (greater than 20mg/d prednisone equivalent for greater than 2 weeks)			
* Evidence for less than 18 years of age is limited. Multidisciplinary consultation with infectious diseases and primary care is recommended		□ Other: Name of Immune modifying Drug			
<b>Outpatient COVID Therapy Assessi</b>	ment:				
□ Attach current medication, herbal, OTC list Patient's Home Pharmacy Contact: Is the patient pregnant? □ YES □ NO □ N/A Existing liver impairment: □ YES □ NO □ UNKNOWN		Existing renal impairment: ☐ YES ☐ NO ☐ UNKNOWN  If YES, enter Serum Creatinine and eGFR ☐ Serum Creatinine (µmol/L): Date: ☐ eGFR (ml/min): Date:			
Referral Attestation (Must be checked to be eligible for treatment)					
□ I affirm that my patient meets above criteria for use and that current medication list is included with referral					
Provider Name (print):  Direct Contact Number (not office line): Provider Fax number:					
· · · · · · · · · · · · · · · · · · ·	lege Number: Signature: Date:				
			= = = = = = = = = = = = = = = =		